The Food and Drug Administration (FDA) has approved the HIV-1 medication ibalizumab-uiyk (Trogarzo, Theratechnologies Inc) for administration by intravenous push. Ibalizumab-uiyk, a long-acting ...
The new approval allows for the 2000mg loading dose to be administered as an IV push rather than a 30-minute IV infusion. The prescribing information for Trogarzo ® (ibalizumab-uiyk) has been updated ...
SAN DIEGO, Feb. 26, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class ...
The approval was based on data from the phase 3 TMB-302 trial that evaluated Trogarzo 800mg administered via IV push once every 2 weeks. The Food and Drug Administration (FDA) has approved Trogarzo ® ...
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results